491 related articles for article (PubMed ID: 32462282)
1. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.
Rizzo E
Naunyn Schmiedebergs Arch Pharmacol; 2020 Jul; 393(7):1153-1156. PubMed ID: 32462282
[TBL] [Abstract][Full Text] [Related]
2. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly L; Druce JD; Catton MG; Jans DA; Wagstaff KM
Antiviral Res; 2020 Jun; 178():104787. PubMed ID: 32251768
[TBL] [Abstract][Full Text] [Related]
3. Metabolomics to Predict Antiviral Drug Efficacy in COVID-19.
Migaud M; Gandotra S; Chand HS; Gillespie MN; Thannickal VJ; Langley RJ
Am J Respir Cell Mol Biol; 2020 Sep; 63(3):396-398. PubMed ID: 32574504
[No Abstract] [Full Text] [Related]
4. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.
DiNicolantonio JJ; Barroso J; McCarty M
Open Heart; 2020 Sep; 7(2):. PubMed ID: 32895293
[No Abstract] [Full Text] [Related]
5. Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?
Jans DA; Wagstaff KM
Cells; 2020 Sep; 9(9):. PubMed ID: 32942671
[TBL] [Abstract][Full Text] [Related]
6. Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing.
Jermain B; Hanafin PO; Cao Y; Lifschitz A; Lanusse C; Rao GG
J Pharm Sci; 2020 Dec; 109(12):3574-3578. PubMed ID: 32891630
[TBL] [Abstract][Full Text] [Related]
7. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach.
Parvez MSA; Karim MA; Hasan M; Jaman J; Karim Z; Tahsin T; Hasan MN; Hosen MJ
Int J Biol Macromol; 2020 Nov; 163():1787-1797. PubMed ID: 32950529
[TBL] [Abstract][Full Text] [Related]
8. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein.
Vankadari N
Int J Antimicrob Agents; 2020 Aug; 56(2):105998. PubMed ID: 32360231
[TBL] [Abstract][Full Text] [Related]
9. Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy.
Jensen JD; Lynch M
Heredity (Edinb); 2020 May; 124(5):619-620. PubMed ID: 32251365
[No Abstract] [Full Text] [Related]
10. Lung tissue distribution of drugs as a key factor for COVID-19 treatment.
Wang Y; Chen L
Br J Pharmacol; 2020 Nov; 177(21):4995-4996. PubMed ID: 32424836
[No Abstract] [Full Text] [Related]
11. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
12. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients.
Camprubí D; Almuedo-Riera A; Martí-Soler H; Soriano A; Hurtado JC; Subirà C; Grau-Pujol B; Krolewiecki A; Muñoz J
PLoS One; 2020; 15(11):e0242184. PubMed ID: 33175880
[TBL] [Abstract][Full Text] [Related]
13. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
Nisole S; Saulnier A; Gatignol A
Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
[No Abstract] [Full Text] [Related]
14. COVID-19 therapeutic options for patients with kidney disease.
Izzedine H; Jhaveri KD; Perazella MA
Kidney Int; 2020 Jun; 97(6):1297-1298. PubMed ID: 32317113
[No Abstract] [Full Text] [Related]
15. Sofosbuvir for COVID-19 infection: A potential candidate.
Gupta R; Dhamija P
Indian J Pharmacol; 2020; 52(3):232-233. PubMed ID: 32874010
[No Abstract] [Full Text] [Related]
16. Discovering small-molecule therapeutics against SARS-CoV-2.
Tiwari V; Beer JC; Sankaranarayanan NV; Swanson-Mungerson M; Desai UR
Drug Discov Today; 2020 Aug; 25(8):1535-1544. PubMed ID: 32574699
[TBL] [Abstract][Full Text] [Related]
17. Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?
Alonso DF; Farina HG
Int J Antimicrob Agents; 2020 Sep; 56(3):106125. PubMed ID: 32739476
[No Abstract] [Full Text] [Related]
18. Macrolide treatment for COVID-19: Will this be the way forward?
Ohe M; Shida H; Jodo S; Kusunoki Y; Seki M; Furuya K; Goudarzi H
Biosci Trends; 2020 May; 14(2):159-160. PubMed ID: 32249257
[TBL] [Abstract][Full Text] [Related]
19. The Battle against COVID 19 Pandemic: What we Need to Know Before we "Test Fire" Ivermectin.
Banerjee K; Nandy M; Dalai CK; Ahmed SN
Drug Res (Stuttg); 2020 Aug; 70(8):337-340. PubMed ID: 32559771
[TBL] [Abstract][Full Text] [Related]
20. Statin therapy and SAR-COV-2: an available and potential therapy?
Abdel-Latif RG; Mohammed S; Elgendy IY
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):333-334. PubMed ID: 32379307
[No Abstract] [Full Text] [Related]
[Next] [New Search]
